Expression and phosphorylation of stathmin correlate with cell migration in esophageal squamous cell carcinoma

Oncology Reports

Volumn 29, Issue 2, 2013, Pages 419-424

  Liu, Fei ^a   Sun, Yu Lin ^a   Xu, Yang ^a   Liu, Fang ^a   Wang, Li Shun ^b   Zhao, Xiao Hang ^a,c  

^a CANCER HOSPITAL   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c NAVY GENERAL HOSPITAL   (China)

Author keywords

Esophageal squamous cell carcinoma; Migration; Phosphorylation; Stathmin

Indexed keywords

PACLITAXEL; SMALL INTERFERING RNA; STATHMIN;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GRADING; CANCER THERAPY; CARCINOGENESIS; CELL MIGRATION; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROTUBULE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TWO DIMENSIONAL ELECTROPHORESIS;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CHI-SQUARE DISTRIBUTION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PACLITAXEL; PHOSPHORYLATION; RNA, SMALL INTERFERING; STATHMIN; TUBULIN MODULATORS; WOUND HEALING;

EID: 84872765867     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2157     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Lin DC, Du XL and Wang MR: Protein alterations in ESCC and clinical implications: a review. Dis Esophagus 22: 9-20, 2009.
3. Steinmetz MO: Structure and thermodynamics of the tubulinstathmin interaction. J Struct Biol 158: 137-147, 2007.
4. Belmont LD and Mitchison TJ: Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 84: 623-631, 1996. (Pubitemid 26071742)
5. Cassimeris L: The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol 14: 18-24, 2002. (Pubitemid 34131652)
6. Manna T, Thrower DA, Honnappa S, Steinmetz MO and Wilson L: Regulation of microtubule dynamic instability in vitro by differentially phosphorylated stathmin. J Biol Chem 284: 15640-15649, 2009.
7. Marklund U, Larsson N, Gradin HM, Brattsand G and Gullberg M: Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics. EMBO J 15: 5290-5298, 1996. (Pubitemid 26336212)
8. Amayed P, Pantaloni D and Carlier MF: The effect of stathmin phosphorylation on microtubule assembly depends on tubulin critical concentration. J Biol Chem 277: 22718-22724, 2002. (Pubitemid 34967251)
9. Niethammer P, Bastiaens P and Karsenti E: Stathmin-tubulin interaction gradients in motile and mitotic cells. Science 303: 1862-1866, 2004. (Pubitemid 38374877)
10. Liu Z, Lu H, Shi H, et al: PUMA overexpression induces reactive oxygen species generation and proteasome-mediated stathmin degradation in colorectal cancer cells. Cancer Res 65: 1647-1654, 2005. (Pubitemid 40478588)
11. Kim J Y, Harvard C, You L, et al: Stathmin is overexpressed in malignant mesothelioma. Anticancer Res 27: 39-44, 2007. (Pubitemid 46363314)
12. Nakashima D, Uzawa K, Kasamatsu A, et al: Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands. Int J Cancer 118: 704-713, 2006. (Pubitemid 43076021)
13. Wang F, Wang LX, He W, Zhu LN, Zhao PR and Fan QX: Expression of stathmin in esophageal squamous cell carcinoma and its biological significance. Nan Fang Yi Ke Da Xue Xue Bao 30: 1552-1557, 2010 (In Chinese).
14. Wang X, Fan QX, Zhao PR and Wang F: Expression and significance of stathmin in esophageal squamous cell carcinoma. J Basic Clin Oncol 120: 372-374, 2007.
15. Wang F, Wang LX, Fan QX and Zhao PR: Inhibitory effects of ASODN of stathmin gene on cultured Eca109 cell lines. J Zhengzhou University (Medical Sciences) 43: 414-418, 2008.
16. Wang Q, Xu Y, Zhao X, et al: A facile one-step in situ function-alization of quantum dots with preserved photoluminescence for bioconjugation. J Am Chem Soc 129: 6380-6381, 2007. (Pubitemid 46799328)
17. Kouzu Y, Uzawa K, Koike H, et al: Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer 94: 717-723, 2006. (Pubitemid 43361904)
18. Trovik J, Wik E, Stefansson IM, et al: Stathmin overexpression identifies high risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res 17: 3368-3377, 2011.
19. Salvesen HB, Das S and Akslen LA: Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 6: 153-159, 2000. (Pubitemid 30064988)
20. Sun Y, Mi W, Cai J, et al: Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. J Proteome Res 7: 3847-3859, 2008.
21. Rana S, Maples PB, Senzer N and Nemunaitis J: Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 8: 1461-1470, 2008.
22. Liu F, Liu F, Sun YL and Zhao XH: Significance of STMN1 expression in esophageal squamous cell carcinoma. World Chin J Digestol 18: 1306-1312, 2010.
23. Sadow PM, Rumilla KM, Erickson LA and Lloyd RV: Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors. Endocr Pathol 19: 97-103, 2008.
24. Bjorklund P, Cupisti K, Fryknas M, et al: Stathmin as a marker for malignancy in pheochromocytomas. Exp Clin Endocrinol Diabetes 118: 27-30, 2010.
25. Xi W, Rui W, Fang L, Ke D, Ping G and Hui-Zhong Z: Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. J Cancer Res Clin Oncol 135: 837-846, 2009.
26. Cheng AL, Huang WG, Chen ZC, et al: Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin Cancer Res 14: 435-445, 2008.
27. Jeon TY, Han ME, Lee Y W, et al: Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer 102: 710-718, 2010.
28. Yuan RH, Jeng YM, Chen HL, et al: Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 209: 549-558, 2006.
29. Gan L, Guo K, Li Y, et al: Up-regulated expression of stathmin may be associated with hepatocarcinogenesis. Oncol Rep 23: 1037-1043, 2010.
30. Kuo MF, Wang HS, Kuo QT, et al: High expression of stathmin protein predicts a fulminant course in medulloblastoma. J Neurosurg Pediatr 4: 74-80, 2009.
31. Lin WC, Chen SC, Hu FC, et al: Expression of stathmin in localized upper urinary tract urothelial carcinoma: correlations with prognosis. Urology 74: 1264-1269, 2009.
32. Su D, Smith SM, Preti M, et al: Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 115: 2453-2463, 2009.
33. Takahashi K and Suzuki K: Membrane transport of WAVE2 and lamellipodia formation require Pak1 that mediates phosphorylation and recruitment of stathmin/Op18 to Pak1-WAVE2-kinesin complex. Cell Signal 21: 695-703, 2009.
34. Ravelli RB, Gigant B, Curmi PA, et al: Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428: 198-202, 2004. (Pubitemid 38374318)
35. Di Paolo G, Antonsson B, Kassel D, Riederer BM and Grenningloh G: Phosphorylation regulates the microtubule-destabilizing activity of stathmin and its interaction with tubulin. FEBS Lett 416: 149-152, 1997. (Pubitemid 27462775)
36. Moreno FJ and Avila J: Phosphorylation of stathmin modulates its function as a microtubule depolymerizing factor. Mol Cell Biochem 183: 201-209, 1998. (Pubitemid 28263906)
37. Antonsson B, Kassel DB, Ruchti E and Grenningloh G: Differences in phosphorylation of human and chicken stathmin by MAP kinase. J Cell Biochem 80: 346-352, 2001.
38. Gadea BB and Ruderman JV: Aurora B is required for mitotic chromatin-induced phosphorylation of Op18/Stathmin. Proc Natl Acad Sci USA 103: 4493-4498, 2006.
39. Chen PW, Lin SJ, Tsai SC, et al: Regulation of microtubule dynamics through phosphorylation on stathmin by Epstein-Barr virus kinase BGLF4. J Biol Chem 285: 10053-10063, 2010.
40. Andersen SS: Spindle assembly and the art of regulating micro-tubule dynamics by MAPs and Stathmin/Op18. Trends Cell Biol 10: 261-267, 2000. (Pubitemid 30387030)
41. Mistry SJ, Bank A and Atweh GF: Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure. Mol Cancer Res 5: 773-782, 2007. (Pubitemid 47294805)
42. Honore S, Pasquier E and Braguer D: Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci 62: 3039-3056, 2005. (Pubitemid 43004753)
43. Cernuda-Morollon E, Millan J, Shipman M, Marelli-Berg FM and Ridley AJ: Rac activation by the T-cell receptor inhibits T cell migration. PLoS One 5: e12393, 2010.
44. Belletti B, Nicoloso MS, Schiappacassi M, et al: Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell 19: 2003-2013, 2008.